Search hospitals > Florida > Orlando
Clinical Neuroscience Solutions, Inc
Claim this profileOrlando, Florida 32801
Global Leader in Depression
Global Leader in Attention Deficit Hyperactivity Disorder (ADHD)
Conducts research for Major Depressive Disorder
Conducts research for Migraine
Conducts research for Coronavirus
184 reported clinical trials
4 medical researchers
Summary
Clinical Neuroscience Solutions, Inc is a medical facility located in Orlando, Florida. This center is recognized for care of Depression, Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder, Migraine, Coronavirus and other specialties. Clinical Neuroscience Solutions, Inc is involved with conducting 184 clinical trials across 94 conditions. There are 4 research doctors associated with this hospital, such as Robert Molpus, M.D, Tatyana Miroshnikova, Robert Bond Molpus, MD, and Michael Edward Dever.Top PIs
Robert Molpus, M.DClinical Neuroscience Solutions, Inc.2 years of reported clinical research
Studies Depression
Studies Attention Deficit Hyperactivity Disorder (ADHD)
9 reported clinical trials
12 drugs studied
Tatyana MiroshnikovaClinical Neuroscience Solutions, Inc.1 year of reported clinical research
Studies Obesity
Studies Chronic Knee Pain
2 reported clinical trials
2 drugs studied
Robert Bond Molpus, MDClinical Neuroscience Solutions, Inc.3 years of reported clinical research
Studies Attention Deficit Hyperactivity Disorder (ADHD)
Studies Migraine
2 reported clinical trials
4 drugs studied
Michael Edward DeverClinical Neuroscience Solutions, Inc.1 year of reported clinical research
Studies Cardiovascular Disease
Studies Obesity
1 reported clinical trial
2 drugs studied
Clinical Trials running at Clinical Neuroscience Solutions, Inc
Depression
Migraine
Obstructive Sleep Apnea
Atopic Dermatitis
Obesity
Coronavirus
Attention Deficit Hyperactivity Disorder (ADHD)
Major Depressive Disorder
COVID-19
Sleep Apnea
Psilocybin
for Depression
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period.
Recruiting1 award Phase 3
Investigational Drug
for Bipolar Depression
This trial is testing a new medication called SEP-4199 CR to see if it can help adults aged 18-65 who have depression from Bipolar I disorder. The study will compare the effects of the medication to see if it reduces symptoms of depression. SEP-4199 has shown antidepressant efficacy in a previous study for bipolar depression.
Recruiting1 award Phase 35 criteria
BHV-7000
for Depression
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Recruiting0 awards Phase 23 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Clinical Neuroscience Solutions, Inc?
Clinical Neuroscience Solutions, Inc is a medical facility located in Orlando, Florida. This center is recognized for care of Depression, Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder, Migraine, Coronavirus and other specialties. Clinical Neuroscience Solutions, Inc is involved with conducting 184 clinical trials across 94 conditions. There are 4 research doctors associated with this hospital, such as Robert Molpus, M.D, Tatyana Miroshnikova, Robert Bond Molpus, MD, and Michael Edward Dever.